PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11477207-9	2001	Finally, cromoglycate or antihistamine drugs significantly reduced ibotenate-induced brain lesions in IL-9-treated Swiss pups.	Ibotenic Acid	67-76	interleukin 9	Mus musculus	102-106	
15649710-4	2005	Pretreatment with TGF-beta1 produced the same effects as IL-9 on ibotenate-induced lesions.	Ibotenic Acid	65-74	interleukin 9	Mus musculus	57-61	
10632101-6	2000	Pups pretreated with interleukin (IL)-1beta, IL-6, IL-9, or tumor necrosis factor-alpha developed significantly larger ibotenate-induced cortical and white matter damage than controls; IL-4 did not produce such an effect.	Ibotenic Acid	119-128	interleukin 9	Mus musculus	51-55	
10632101-7	2000	In a similar manner, IL-9-overexpressing transgenic pups developed ibotenate-induced brain lesions, which were significantly larger than those induced in nontransgenic control pups.	Ibotenic Acid	67-76	interleukin 9	Mus musculus	21-25	
12644245-4	2003	Intracerebral injection of the glutamatergic analogue ibotenate to newborn mice induces cortical plate and white matter lesions mimicking the brain damage associated with cerebral palsy, and pretreatment with proinflammatory cytokines such as interleukin-1-beta or with interleukin-9 significantly exacerbates these lesions.	Ibotenic Acid	54-63	interleukin 9	Mus musculus	270-283